177Lu-Pentixather的生物动力学与剂量学
结果显示骨髓和髓外病灶的吸收剂量足以作为干细胞移植前大剂量化疗的辅助治疗。
要点
- 177Lu-pentixather在肾脏、肝脏、脾脏和骨髓中有明显摄取。
- 每GBq 177Lu-pentixather对肾脏、肝脏、脾脏和骨髓的中位吸收剂量分别为0.91、0.71、0.58和0.47 Gy。
- 每GBq 90Y-pentixather对上述器官的中位吸收剂量分别为3.75、1.61、1.66和1.06 Gy。
核心结论
- 在血液肿瘤患者中,骨髓和髓外病灶的吸收剂量足以作为干细胞移植前大剂量化疗的辅助治疗。
主要发现
- 肾脏、肝脏、脾脏和骨髓出现摄取增高,每GBq 177Lu-pentixather的中位吸收剂量分别为0.91 Gy(范围0.38-3.47 Gy)、0.71 Gy(范围0.39-1.17 Gy)、0.58 Gy(范围0.34-2.26 Gy)和0.47 Gy(范围0.14-2.33 Gy)。
- 每GBq 90Y-pentixather对上述器官的中位吸收剂量分别为3.75 Gy(范围1.48-12.2 Gy)、1.61 Gy(范围1.14-2.97 Gy)、1.66 Gy(范围0.97-6.69 Gy)和1.06 Gy(范围0.27-4.45 Gy)。
- 大多数组织中,177Lu-pentixather给药后第一天活度增加,随后衰减,肾脏平均有效半衰期为41±10小时(范围24-64小时),肝脏、脾脏和骨髓中位半衰期分别为109、86和92小时。
- 单肾最大摄取为2.2%±1.0%(范围0.6%-5.1%)。
- 在无特异性摄取的器官中,每GBq 90Y-pentixather估计膀胱和邻近累积器官的组织(如肾上腺、骨表面和胆囊)吸收剂量超过0.3 Gy。
临床怎么用
- 基于剂量学数据,177Lu-pentixather和90Y-pentixather可用于血液肿瘤患者干细胞移植前大剂量化疗的辅助治疗。
局限性
- 回顾性研究,样本量有限,部分器官剂量基于模型估算而非直接测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The chemokine receptor 4 (CXCR4), which is overexpressed in many solid and hematologic malignancies, can be targeted for radiopeptide therapy via the antagonist pentixather. The biokinetics and dosimetry of 177Lu-pentixather and 90Y-pentixather were analyzed in this study. Methods: This retrospective study was a standardized reevaluation of data collected for treatment planning. Nineteen patients with complete sets of planar whole-body scans over at least 4 d and a single SPECT/CT scan after administration of 200 MBq of 177Lu-pentixather were included. Kinetics were measured in the whole body, in tissues with activity retention, and in 10 individuals in the blood. Time-integrated activity coefficients and tissue-absorbed doses were derived. Results: Increased uptake of pentixather was observed in the kidneys, liver, spleen, and bone marrow, inducing respective median absorbed doses of 0.91 Gy (range, 0.38-3.47 Gy), 0.71 Gy (range, 0.39-1.17 Gy), 0.58 Gy (range, 0.34-2.26 Gy), and 0.47 Gy (range, 0.14-2.33 Gy) per GBq of 177Lu-pentixather and 3.75 Gy (range, 1.48-12.2 Gy), 1.61 Gy (range, 1.14-2.97 Gy), 1.66 Gy (range, 0.97-6.69 Gy), and 1.06 Gy (range, 0.27-4.45 Gy) per GBq of 90Y-pentixather. In most tissues, activity increased during the first day after the administration of 177Lu-pentixather and afterward decayed with mean effective half-lives of 41 ± 10 h (range, 24-64 h) in the kidneys and median half-lives of 109, 86, and 92 h in the liver, spleen, and bone marrow, respectively. Maximum uptake per kidney was 2.2% ± 1.0% (range, 0.6%-5.1%). In organs showing no specific uptake, absorbed doses exceeding 0.3 Gy/GBq of 90Y-pentixather were estimated for the urinary bladder and for tissues adjacent to accumulating organs such as the adrenal glands, bone surface, and gallbladder. Dose estimates for tumors and extramedullary lesions ranged from 1.5 to 18.2 Gy/GBq of 90Y-pentixather. Conclusion: In patients with hematologic neoplasms, absorbed doses calculated for bone marrow and extramedullary lesions are sufficient to be effective as an adjunct to high-dose chemotherapies before stem cell transplantation.
引用
- Hänscheid H, Schirbel A, Hartrampf P, et al. Biokinetics and Dosimetry of 177Lu-Pentixather. J Nucl Med. 2021. PMID: 34413147. doi:10.2967/jnumed.121.262295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。